In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PharmAthene, Inc.

http://www.pharmathene.com/

Latest From PharmAthene, Inc.

Finance Watch: Have Biopharma IPOs Hit Their Limit?

Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.

Financing Business Strategies

China Cell Therapy Party On: $500m+ Raised In JW IPO, Other Rounds

It's been a big week for cell therapy developers in China with well over $500m raised through an IPO and large new funding rounds for several other ventures.

Gene Therapy Financing

Finance Watch: Big VC Money Backs Tech-Enabled Drug Discovery

Private Company Edition: XtalPi raised $318.8m for its AI-based drug discovery platform and machine learning-enabled Flagship start-up Valo Health has brought in nearly $100m. XtalPi had one of three recent venture capital mega-rounds for China-based companies.

Financing Artificial Intelligence

New Designations Set To Speed Hemlibra, CAR-T In China

China is set to grant priority reviews to major biologics from Roche, the first CAR-T therapy from Wuxi Juno, and breakthrough therapy designation to a pediatric respiratory antiviral from ArkBio.

China Rare Diseases
See All

Company Information

UsernamePublicRestriction

Register